

## Zitrol XR®

(Glipizide Extended Release Tablets)

### Composition

**Zitrol XR® 2.5:** Each extended release tablet contains Glipizide BP 2.5 mg.

**Zitrol XR® 5 :** Each extended release tablet contains Glipizide BP 5 mg.

**Zitrol XR® 10 :** Each extended release tablet contains Glipizide BP 10 mg.

**Zitrol XR®** (Glipizide) is an oral blood-glucose-lowering drug of the sulfonylurea class formulated as a once-a-day controlled release tablet for oral use.

**Clinical Pharmacology:** *Mechanism of Action:* Glipizide lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells. The extrapancreatic effects of Glipizide are increase in insulin sensitivity and decrease in hepatic glucose production.

*Pharmacokinetics and Metabolism:* The absolute bioavailability of glipizide is 100%. Steady-state effective plasma concentrations are achieved by at least the fifth day of dosing with the preparation in type 2 diabetic patients younger than 65 years. Approximately 1 to 2 days longer are required for patients >65 years. No accumulation of drug is likely in patients during chronic dosing.

### Indications and Usage

Zitrol XR Extended Release Tablet is indicated as an adjunct to diet in patients with type 2 diabetes. The preparation can be used as combination therapy with other oral hypoglycemic agents and with insulin.

### Contraindications

- ◆ Known hypersensitivity to glipizide.
- ◆ Type 1 diabetes, diabetic ketoacidosis, with or without coma.

**Warnings:** The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin.

**Precautions:** *Renal and Hepatic Disease:* The pharmacokinetics of glipizide may be affected.

*GI Disease:* Markedly reduced GI retention times may influence the pharmacokinetic profile of the drug.

*Hypoglycemia:* All sulfonylurea drugs are capable of producing severe hypoglycemia.

*Drug Interactions:* The hypoglycemic action of sulfonylureas may be potentiated by NSAIDs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins,

monoamine oxidase inhibitors, and beta-adrenergic blocking agents. Certain drugs tend to produce hyperglycemia i.e. thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.

*Pregnancy:* Pregnancy category C.

*Nursing Mothers:* It is not known whether glipizide is excreted in human milk or not.

*Pediatric Use:* Safety and effectiveness in children have not been established.

*Geriatric Use:* There were no overall differences in effectiveness or safety between younger and older patients.

**Adverse Reactions:** The most potential adverse reaction is hypoglycemia (1% to 3.4%). Other side effects reported were asthenia, headache, dizziness, nervousness, tremor, diarrhea, flatulence.

**Overdosage:** There is no well-documented experience with Glipizide Extended Release Tablets overdosage in humans.

**Dosage and Administration:** The usual starting dose is 5 mg per day, given with breakfast. Dosage adjustment should be based on glycemic control. If no improvement is seen after three months of therapy with a higher dose, the previous dose should be resumed. Most patients will be controlled with 5 mg to 10 mg taken once daily. The maximum recommended daily dose is 20 mg. Patients receiving immediate release or intermediate release glipizide may be switched safely to the extended release preparation once-a-day at the nearest equivalent total daily dose.

**Combination Use:** Zitrol XR should be initiated at the lowest recommended dose for combination therapy. Patients with stable type 2 diabetes receiving insulin may be transferred safely to treatment with the extended release tablets.

**Storage Condition:** The tablets should be protected from moisture and humidity and stored at room temperature (below 30° C).

### How Supplied

**Zitrol XR® 2.5:** Box containing thirty (3 X 10's) 2.5 mg Glipizide Extended Release Tablets in blister strips.

**Zitrol XR® 5:** Box containing fifty (5 X 10's) 5mg Glipizide Extended Release Tablets in blister strips.

**Zitrol XR® 10:** Box containing thirty (3 X 10's) 10 mg Glipizide Extended Release Tablets in blister strips.